Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxychloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 1.00 |
| ▸ | TLR7 known ✓ | Q9NYK1 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | CGAS | Q8N884 | 1/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxychloroquine SCHEMBL31023589 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8170 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29430237 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL6746375 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL9047 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29359553 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL30107680 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL23854335 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL4742350 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL236192 | 0.99 | KCNH2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213324-B | Hydroxychloroquine eutectic, preparation method thereof, content determination method and application | 华南理工大学 | 2024-02-23 | — | — | CN | claimed |
| CN-114315716-B | Hydroxychloroquine eutectic, preparation method thereof, content determination method and application | 华南理工大学 | 2024-02-23 | — | — | CN | claimed |
| WO-2022256426-A1 | TREATMENT OF ANTIPHOSPHOLIPID SYNDROME USING S-HYDROXYCHLOROQUINE | GENOVATE BIOTECHNOLOGY CO. LTD. (TW) | 2022-12-08 | — | — | WO | claimed |
| CN-114213324-A | Hydroxychloroquine eutectic crystal, preparation method, content determination method and application thereof | 华南理工大学 | 2022-03-22 | — | — | CN | claimed |
| CN-114057640-A | Asymmetric synthesis method of optically pure (R)/(S) -hydroxychloroquine side chain | 凯特立斯（深圳）科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113440528-A | Application of optically pure 4-aminoquinoline compound in preparation of drugs for treating coronavirus | 上海华理生物医药股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| US-5314894-A | (S)-(+)-hydroxychloroquine | STERLING WINTHROP INC. (US) | 1994-05-24 | — | — | US | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025213007-A1 | S-HYDROXYCHLOROQUINE, OPTIONALLY WITH TAUROURSODEOXYCHOLIC ACID AND/OR 3,3'-DIINDOLYLMETHANE, FOR TREATING AND/OR PREVENTING NEUROLOGICAL DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-09 | — | — | WO | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240325312-A1 | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule | INCANNEX HEALTHCARE PTY LTD (FKA INCANNEX HEALTHCARE LIMITED) (AU) | 2024-10-03 | — | — | US | disclosed |
| WO-2024155775-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240238272-A1 | TREATMENT OF ANTIPHOSPHOLIPID SYNDROME USING S-HYDROXYCHLOROQUINE | GENOVATE BIOTECHNOLOGY CO. LTD. (TW) | 2024-07-18 | — | — | US | disclosed |
| WO-2021217574-A1 | TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2021-11-04 | — | — | WO | disclosed |
| CN-113440528-A | Application of optically pure 4-aminoquinoline compound in preparation of drugs for treating coronavirus | 上海华理生物医药股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3749773-A1 | VIRAL VECTOR TRANSDUCTION | Oxford University Innovation Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019155016-A1 | VIRAL VECTOR TRANSDUCTION | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-15 | — | — | WO | disclosed |
| EP-0588430-B1 | Use of (S)-(+)-Hydroxychloroquine | SANOFI SA (FR) | 1998-05-27 | — | — | EP | disclosed |
| US-5314894-A | (S)-(+)-hydroxychloroquine | STERLING WINTHROP INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0588430-A1 | (S)-(+)-Hydroxychloroquine | STERLING WINTHROP INC. (US) | 1994-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325312-A1 | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule | CNR2, CNR1, TPMT | TLR9 101/4885TLR7 261/4885CHRM2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.